Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2020 Feb 20;58(Suppl S29):1-464.
doi: 10.4193/Rhin20.600.

European Position Paper on Rhinosinusitis and Nasal Polyps 2020

W J Fokkens  1 V J Lund  2 C Hopkins  3 P W Hellings  1   4   5 R Kern  6 S Reitsma  1 S Toppila-Salmi  7 M Bernal-Sprekelsen  8 J MullolI Alobid  9 W Terezinha Anselmo-Lima  10 C Bachert  5   11 F Baroody  12 C von Buchwald  13 A Cervin  14   15 N Cohen  16 J Constantinidis  17 L De Gabory  18 M Desrosiers  19 Z Diamant  20   21   22 R G Douglas  23 P H Gevaert  24 A Hafner  25 R J Harvey  26 G F Joos  27 L Kalogjera  28   29 A Knill  30 J H Kocks  31 B N Landis  32 J Limpens  33 S Lebeer  34 O Lourenco  35 C Meco  36   37 P M Matricardi  38 L O'Mahony  39 C M Philpott  40   41 D Ryan  42   43 R Schlosser  44 B Senior  45 T L Smith  46 T Teeling  47 P V Tomazic  48 D Y Wang  49 D Wang  50   51 L Zhang  52 A M Agius  53 C Ahlstrom-Emanuelsson  54 R Alabri  55 S Albu  56 S Alhabash  57 A Aleksic  58 M Aloulah  59 M Al-Qudah  60 S Alsaleh  61 M A Baban  62 T Baudoin  63 T Balvers  64 P Battaglia  65 J D Bedoya  66 A Beule  67 K M Bofares  68 I Braverman  69 E Brozek-Madry  70 B Richard  71 C Callejas  72 S Carrie  73 L Caulley  74 D Chussi  75 E de Corso  76 A Coste  77 U El Hadi  78 A Elfarouk  79 P H Eloy  80 S Farrokhi  81   82 G Felisati  83 M D Ferrari  64 R Fishchuk  84 W Grayson  85 P M Goncalves  86 B Grdinic  87 V Grgic  28   88 A W Hamizan  89 J V Heinichen  90 S Husain  91 T I Ping  92 J Ivaska  93 F Jakimovska  94 L Jovancevic  95 E Kakande  96 R Kamel  97 S Karpischenko  98   99 H H Kariyawasam  100 H Kawauchi  101 A Kjeldsen  102 L Klimek  103 A Krzeski  104 G Kopacheva Barsova  105 S W Kim  106 D Lal  107 J J Letort  108 A Lopatin  109   110 A Mahdjoubi  111 A Mesbahi  112 J Netkovski  113 D Nyenbue Tshipukane  114 A Obando-Valverde  115 M Okano  116 M Onerci  117 Y K Ong  118 R Orlandi  119 N Otori  120 K Ouennoughy  121 M Ozkan  122 A Peric  123 J Plzak  124 E Prokopakis  125 N Prepageran  126 A Psaltis  127 B Pugin  128 M Raftopulos  1   129 P Rombaux  130 H Riechelmann  131 S Sahtout  132 C-C Sarafoleanu  133 K Searyoh  134 C-S Rhee  135 J Shi  136 M Shkoukani  137 A K Shukuryan  138 M Sicak  139 D Smyth  140 K Sindvongs  141 T Soklic Kosak  142 P Stjarne  143 B Sutikno  144 S Steinsvag  145 P Tantilipikorn  146 S Thanaviratananich  137 T Tran  147 J Urbancic  148 A Valiulius  149 C Vasquez de Aparicio  150 D Vicheva  151 P M Virkkula  152 G Vicente  153 R Voegels  154 M M Wagenmann  155 R S Wardani  156 A Welge-Lussen  157 I Witterick  74 E Wright  158 D Zabolotniy  159 B Zsolt  160 C P Zwetsloot  161
Affiliations
Practice Guideline

European Position Paper on Rhinosinusitis and Nasal Polyps 2020

W J Fokkens et al. Rhinology. .

Abstract

The European Position Paper on Rhinosinusitis and Nasal Polyps 2020 is the update of similar evidence based position papers published in 2005 and 2007 and 2012. The core objective of the EPOS2020 guideline is to provide revised, up-to-date and clear evidence-based recommendations and integrated care pathways in ARS and CRS. EPOS2020 provides an update on the literature published and studies undertaken in the eight years since the EPOS2012 position paper was published and addresses areas not extensively covered in EPOS2012 such as paediatric CRS and sinus surgery. EPOS2020 also involves new stakeholders, including pharmacists and patients, and addresses new target users who have become more involved in the management and treatment of rhinosinusitis since the publication of the last EPOS document, including pharmacists, nurses, specialised care givers and indeed patients themselves, who employ increasing self-management of their condition using over the counter treatments. The document provides suggestions for future research in this area and offers updated guidance for definitions and outcome measurements in research in different settings. EPOS2020 contains chapters on definitions and classification where we have defined a large number of terms and indicated preferred terms. A new classification of CRS into primary and secondary CRS and further division into localized and diffuse disease, based on anatomic distribution is proposed. There are extensive chapters on epidemiology and predisposing factors, inflammatory mechanisms, (differential) diagnosis of facial pain, allergic rhinitis, genetics, cystic fibrosis, aspirin exacerbated respiratory disease, immunodeficiencies, allergic fungal rhinosinusitis and the relationship between upper and lower airways. The chapters on paediatric acute and chronic rhinosinusitis are totally rewritten. All available evidence for the management of acute rhinosinusitis and chronic rhinosinusitis with or without nasal polyps in adults and children is systematically reviewed and integrated care pathways based on the evidence are proposed. Despite considerable increases in the amount of quality publications in recent years, a large number of practical clinical questions remain. It was agreed that the best way to address these was to conduct a Delphi exercise . The results have been integrated into the respective sections. Last but not least, advice for patients and pharmacists and a new list of research needs are included. The full document can be downloaded for free on the website of this journal: http://www.rhinologyjournal.com.

PubMed Disclaimer

Similar articles

Cited by

Publication types

LinkOut - more resources